Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Ibrutinib, a first-in-class, once-daily Bruton’s tyrosine kinase inhibitor, is FDA approved for all patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Prior phase 3 RESONATE study data established the superiority of ibrutinib to ofatumumab in patients with relapsed/refractory CLL or SLL, as measured by progression-free survival (PFS), overall survival (OS), and response (Byrd. NEJM. 2014). Researchers reported updated safety and efficacy results from the RESONATE trial, with up to 4 years’ follow-up.

In the study, patients received ibrutinib 420 mg orally until disease progression, or ofatumumab for up to 24 weeks. At median 9-month follow-up, the Data Monitoring Committee declared the superiority of ibrutinib versus ofatumumab for PFS and OS, and ibrutinib access was recommended for all patients receiving ofatumumab.

A total of 391 patients were randomized to receive ibrutinib (n = 195) or ofatumumab (n = 196). Patients’ median age was 67 years; 57% had Rai stage III/IV disease. After median follow-up of 44 months, PFS was significantly longer for ibrutinib versus ofatumumab (P <0.0001); median PFS was not reached for ibrutinib versus 8 months for ofatumumab. Furthermore, 59% of patients receiving ibrutinib achieved 3-year PFS compared with 3% of patients receiving ofatumumab. A favorable trend in PFS was also seen with ibrutinib for the del11q subgroup; however, outcomes did not achieve significance for other genetic abnormalities. Approximately two-thirds of patients in the ofatumumab arm crossed over to ibrutinib after losing response. OS was longer for ibrutinib versus ofatumumab; median OS was not reached for either arm. The OS at 3 years for patients receiving ibrutinib was nearly three-quarters (74%). Treatment-related toxicities were generally well-tolerated by patients receiving ibrutinib, and adverse event rates were consistent with earlier data. The incidence of most grade 3 or grade 4 adverse events decreased from year 1 to years 2 and 3. Discontinuation was most frequently due to disease progression (27%) and adverse events (12%).

Long-term treatment with ibrutinib in the international phase 3 RESONATE study was well-tolerated and continues to show sustained PFS and OS regardless of high-risk cytogenetics. These data add to the body of evidence supporting ibrutinib as a cornerstone therapeutic option in patients with CLL.

Byrd JC, et al. ASCO Abstract 7510.

Related Items
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: September 5, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME